Foresite Capital Management VI LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Foresite Capital Management VI LLC reported 14 stock positions worth $224.4 million. Its top holding was CG Oncology (CGON) at 28.4% of the portfolio, followed by Alumis (ALMS, 14.7%) and Centessa Pharmaceuticals (CNTA, 9.4%).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0002013341
- Portfolio Value
- $224.4M (Q4 2024)
- SEC Filing
- 0001104659-25-013964 ↗ filed Feb 14, 2025
Holdings Value
Holdings 14 stocks · $224.4M
| CGON CG Oncology Inc. | 28.39% | 2,221,474 | $63.7M | — |
| ALMS Alumis Inc. | 14.72% | 4,202,670 | $33.0M | — |
| CNTA Centessa Pharmaceuticals Ltd. | 9.35% | 1,253,379 | $21.0M | — |
| RAPT THERAPEUTICS INC | 8.80% | 12,500,000 | $19.8M | — |
| BCAX Bicara Therapeutics Inc. | 7.37% | 950,000 | $16.5M | — |
| EWTX Edgewise Therapeutics Inc. | 6.96% | 585,000 | $15.6M | — |
| GPCR Structure Therapeutics Inc. | 5.08% | 420,000 | $11.4M | — |
| AKRO Akero Therapeutics Inc. | 4.52% | 365,000 | $10.2M | — |
| CRVS Corvus Pharmaceuticals Inc. | 3.77% | 1,581,233 | $8.5M | — |
| CGEM Cullinan Therapeutics Inc. | 3.44% | 634,558 | $7.7M | — |
| ALLO Allogene Therapeutics Inc. | 3.27% | 3,448,275 | $7.3M | — |
| KYMR Kymera Therapeutics Inc. | 2.62% | 146,332 | $5.9M | — |
| CASIF Casi Pharmaceuticals Inc. | 1.68% | 1,329,383 | $3.8M | — |
| VRDN Viridian Therapeutics Inc. | 0.02% | 1,974 | $38K | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $642.6M | CGON, ALMS, SPTX, DNLI, CLDX |
| Q1 2026 | 17 | $460.3M | CGON, ALMS, CNTA, CRVS, DNLI |
| Q4 2025 | 12 | $330.8M | CGON, RAPT, ALMS, CNTA, VSTM |
| Q3 2025 | 12 | $258.9M | CGON, RAPT, CNTA, VSTM, ALMS |
| Q2 2025 | 20 | $177.9M | CGON, CNTA, AKRO, ALMS, RAPT |
| Q1 2025 | 14 | $182.5M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, AKRO |
| Q4 2024 | 14 | $224.4M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, BCAX |